Securities code: 688276 Securities abbreviation: Baike Biotechnology Announcement No.: 2024-047

Changchun Baike Biotechnology Co., Ltd

Announcement on the adjustment of core technical personnel

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Important Content Notes:

Changchun Baike Biotechnology Co., Ltd. (hereinafter referred to as "the company") according to the strategic development plan, comprehensive consideration of the management and implementation of the company's research and development projects, the first meeting of the sixth board of directors of the company deliberated and approved, the company's existing core technical personnel were adjusted: the original core technical personnel Mr. Zhu Changlin due to the adjustment of work content, no longer identified as the company's core technical personnel, still continue to serve in the company.

The company has signed relevant agreements with Mr. Zhu Changlin, and there are no disputes or potential disputes related to job results and intellectual property rights. The adjustment of core technical personnel will not affect the integrity of the company's core technology and patent ownership, nor will it have a significant adverse impact on the company's core competitiveness, technical advantages, business and product innovation capabilities.

First, the specific situation of the adjustment of core technical personnel

(1) Adjust the situation of core technical personnel

Mr. Zhu Changlin, the company's core technical personnel, is no longer recognized as a core technical personnel due to the adjustment of work content, and still continues to work in the company.

1. The specific situation of core technical personnel

Mr. Zhu Changlin, born in January 1968, a member of the Communist Party of China, graduated from the former Bethune Medical University (now Bethune Medical Department of Jilin University) with a bachelor's degree, is a senior engineer, and is currently the secretary of the party branch, the chairman of the labor union and the chief engineer of the company. He has served as the production team leader of the measles vaccine room of the former Changchun Institute of Biological Products, and the director of the mumps vaccine workshop and the director of the research office of Changchun Changsheng Biotechnology Co., Ltd. He joined the Company in October 2004 and successively served as R&D Director, Assistant General Manager and Chief Engineer of the Company, during which he was mainly engaged in the research and development of biological vaccines

and industrialization research work, leading or participating in a number of R&D projects such as live attenuated varicella vaccine project, live attenuated herpes zoster vaccine, freeze-dried nasal spray live attenuated influenza vaccine, etc.

2. Intellectual property rights

The company enjoys the ownership of the intellectual property rights formed by the above-mentioned personnel during their tenure with the company. There is no dispute or potential dispute between the Company and the above-mentioned persons over the ownership of service invention patents, nor does it affect the integrity of the Company's intellectual property ownership.

3. Signed agreements and performance

The company has signed a labor contract and a confidentiality agreement with the above-mentioned core technical personnel. Since the signing of the aforesaid agreement, the above-mentioned core technical personnel have strictly performed the obligations and responsibilities agreed in the agreement and complied with the relevant commitments. As of the disclosure date of this announcement, the company has not found that the above-mentioned personnel have violated the above-mentioned relevant agreements.

(2) The situation of core technical personnel after adjustment

As of the disclosure date of this announcement, the company's original core technical personnel are 6 people, and the existing core technical personnel are 5 people, and the core technical personnel before and after this adjustment are as follows:

Period: Name of core technical personnel

Before this adjustment, Kong Wei, Jiang Chunlai, Wei Wei, Liu Dawei, Zhu Changlin, and Shi Nianmin

After this adjustment, Kong Wei, Jiang Chunlai, Wei Wei, Liu Dawei, and Shi Nianmin

Second, the impact of the adjustment of core technical personnel on the company

Since its establishment in 2004, the company has been mainly committed to the research and development, production and sales of innovative biological drugs. After years of accumulation, a professional R&D system has been established, led by scientists and core technical personnel engaged in biotechnology R&D, a professional, stable and experienced R&D team has been created, and a professional R&D system has been established after years of accumulation. As of December 31, 2022, December 31, 2023 and June 30, 2024, the number of R&D personnel of the Company was 132, 134 and 139 respectively, accounting for 10.54%, 10.80% and 10.78% of the total number of employees of the Company, respectively.

After the adjustment of the core technical personnel, the original core technical personnel are still in the company and perform their duties normally, which will not have a significant adverse impact on the company's product development and operation management. There are no disputes or potential disputes involving service inventions in the adjustment of the company's core technical personnel, which will not affect the integrity of the company's core technology and patent ownership, nor will it have a substantial impact on the company's core competitiveness, technological advantages, business and product innovation capabilities.

3. Measures taken by the company

As of the disclosure date of this announcement, the adjustment of the work content of the company's relevant core technical personnel has been completed, and the company's various R&D projects have been progressing in an orderly manner. In the future, the company will always adhere to the concept of innovation as the basic vitality of the enterprise, focus on optimizing the R&D project management mechanism, and coordinate the layout of long-term, medium-term and short-term R&D projects. Focus on innovative vaccines, monoclonal antibodies and other superior products of the company, and realize the production generation, R&D generation, and reserve generation. At the same time, the company will continue to improve the construction of the R&D team, build a solid talent echelon, and continue to enhance the company's comprehensive technological innovation capabilities.

4. Verification opinions of the sponsor institution

After verification, the sponsor believes that the structure of the company's R&D team is complete, and the R&D team and core technical personnel are generally relatively stable; The ownership of the technical achievements related to the R&D projects that Mr. Zhu Changlin participated in during his work in the company belongs to the company, and the adjustment of his position will not affect the integrity of the company's patent rights; The company's R&D projects are progressing in a normal and orderly manner, and the adjustment of core technical personnel has not had a significant adverse impact on the company's daily operation, core competitiveness and ability to continue operations. The sponsor has no objection to the company's adjustment of core technical personnel.

5. Attachments to online announcements

"CITIC Securities Co., Ltd. on the Verification of Changchun Baike Biotechnology Co., Ltd. Adjustment of Core Technical Personnel".

The announcement is hereby made.

Board of Directors of Changchun Baike Biotechnology Co., Ltd

December 11, 2024